No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
www.lonza.comNo one on the platform currently holds LONN.SW.
No tracked institution reports a position in LONN.SW as of their last filing.
No one on the platform has traded LONN.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 19.2% | 7.7% | ||||
| Profit Margin % | -4.2% | 18.2% | 16.1% | |||
| Free Cash Flow Margin % | -3.1% | -5.1% | 1.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.1B | -5.9% | $18.21 | $17.29–$19.50 | — | 18 |
| 2027 | $7.9B | +11.5% | $21.64 | $20.27–$23.41 | — | 19 |
| 2028 | $8.9B | +11.9% | $25.16 | $17.74–$27.40 | — | 18 |
| 2029 | $10.0B | +12.8% | $29.73 | $28.53–$31.27 | — | 9 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-22 | $8.70 | $8.22 | -5.5% |
| 2026-01-28 | $9.25 | $8.40 | -9.2% |
| 2025-07-23 | $7.08 | $7.53 | +6.4% |
| 2025-05-14 | $7.99 | $7.99 | +0.0% |
| 2024-07-25 | $4.99 | $6.90 | +38.3% |
| 2024-01-26 | $6.85 | $6.27 | -8.5% |
| 2023-07-21 | $6.72 | $5.52 | -17.9% |
| 2023-01-25 | $6.85 |
| $6.27 |
| -8.5% |
| $3.2B |
| — |
| SKAN.SWSKAN Group AG | $63.20 | +0.64% | $1.4B | — |
| SOON.SWSonova Holding AG | $228.20 | -0.61% | $13.6B | — |
Source: Financial Modeling Prep · peers by sector/industry